Thema: INE376G01013
Biocon, INE376G01013
securities-and-exchange-7499697_1920.jpg - Foto: THN
Biocon stock faces mixed Q2 as profit drops 52 percent
Biocon stock enters the second half of FY27 with biosimilar launches and insulin demand in focus. Management expects stronger growth after shipment delays shifted revenue into October.
ad-hoc-news.de, heute 01:05 Uhr
Biocon, INE376G01013
Biocon secures Q1 2027 Pebrilzo launch as Motilal Oswal ...
Pebrilzo may launch in Europe in Q1 2027 and the US in Q3 2028. Biocon stock posted INR 43.36 billion revenue in Q1 FY27.
ad-hoc-news.de, 25.10.26 00:16 Uhr
Biocon, INE376G01013
Biocon secures Pebrilzo dates as Axis sets INR 424 target ...
Pebrilzo targets Europe in 2027 and the US in 2028. Biocon stock posted INR 43.36 billion revenue, up 10.00 percent year over year.
ad-hoc-news.de, 20.10.26 01:10 Uhr
Biocon, INE376G01013
Biocon receives UK insulin approval and MarketsMOJO downgrades ...
Axis Direct set a INR 424 target for Biocon stock on September 21, 2026. Q1 FY27 revenue rose 10.00 percent to INR 43.36 billion.
ad-hoc-news.de, 02.10.26 14:43 Uhr
Biocon, INE376G01013
Biocon stock draws support after EMA recommends Pertuzumab ...
An EMA recommendation for Biocon's Pertuzumab biosimilar supports the latest analyst case. Q1 FY27 biosimilars revenue rose 16.00 percent to INR 28.55 billion.
ad-hoc-news.de, 30.09.26 10:10 Uhr
Biocon, INE376G01013
Biocon stock reports 10.00 percent Q1 FY27 revenue growth ...
Biocon stock posted INR 43.36 billion in Q1 FY27 revenue, up 10.00 percent year over year. An analyst model lifted fair value to INR 446.89.
ad-hoc-news.de, 29.09.26 16:00 Uhr
Biocon, INE376G01013
Biocon stock holds steady as investors digest Q1 FY27 earnings ...
Biocon stock reflects Q1 FY27 results with consolidated revenue of INR 4,336 crore and net profit of INR 141 crore as of August 2026. The market now weighs margins and biosimilars ...
ad-hoc-news.de, 19.09.26 21:49 Uhr
